384 related articles for article (PubMed ID: 17452481)
1. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
Almyroudis NG; Sutton DA; Fothergill AW; Rinaldi MG; Kusne S
Antimicrob Agents Chemother; 2007 Jul; 51(7):2587-90. PubMed ID: 17452481
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
Pastor FJ; Ruíz-Cendoya M; Pujol I; Mayayo E; Sutton DA; Guarro J
Antimicrob Agents Chemother; 2010 Nov; 54(11):4550-5. PubMed ID: 20805397
[TBL] [Abstract][Full Text] [Related]
3. Antifungal agents in children.
Steinbach WJ
Pediatr Clin North Am; 2005 Jun; 52(3):895-915, viii. PubMed ID: 15925667
[TBL] [Abstract][Full Text] [Related]
4. Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
Manfredi R; Sabbatani S
Scand J Infect Dis; 2006; 38(10):950-1. PubMed ID: 17008248
[TBL] [Abstract][Full Text] [Related]
5. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
[TBL] [Abstract][Full Text] [Related]
6. Antifungal pharmacotherapy for neonatal candidiasis.
Bliss JM; Wellington M; Gigliotti F
Semin Perinatol; 2003 Oct; 27(5):365-74. PubMed ID: 14626500
[TBL] [Abstract][Full Text] [Related]
7. [Systemic antifungal agents].
Lumbreras C; Lizasoain M; Aguado JM
Enferm Infecc Microbiol Clin; 2003; 21(7):366-79; quiz 380, 390. PubMed ID: 14525693
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole for candidosis: an important addition?
Graybill JR
Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
[No Abstract] [Full Text] [Related]
10. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Gilgado F; Serena C; Cano J; Gené J; Guarro J
Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
[TBL] [Abstract][Full Text] [Related]
13. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
Diekema DJ; Messer SA; Hollis RJ; Jones RN; Pfaller MA
J Clin Microbiol; 2003 Aug; 41(8):3623-6. PubMed ID: 12904365
[TBL] [Abstract][Full Text] [Related]
14. [Three cases of fungemia caused by Blastoschizomyces capitatus].
Koç AN; Copur Çiçek A; Kaynar L; Sav H; Kasap Tekinşen FF; Atalay MA
Mikrobiyol Bul; 2013 Oct; 47(4):734-41. PubMed ID: 24237444
[TBL] [Abstract][Full Text] [Related]
15. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
16. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
[TBL] [Abstract][Full Text] [Related]
17. Combined therapies in a murine model of blastoschizomycosis.
Serena C; Rodríguez MM; Mariné M; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2007 Jul; 51(7):2608-10. PubMed ID: 17452487
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
Laverdiere M; Hoban D; Restieri C; Habel F
J Antimicrob Chemother; 2002 Jul; 50(1):119-23. PubMed ID: 12096017
[TBL] [Abstract][Full Text] [Related]
19. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
20. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
